(Total Views: 353)
Posted On: 02/02/2019 11:26:49 AM
Post# of 72446
I hold OM + IBD worth much, much more than you do. IBD alone is nearly a $40B/yr problem and a pill with little to no side effects that can work on all areas should be worth revenues of a handful of $B/yr in my estimation.
The recent gastric test showed very positive results for the successful formulation of such a pill - again IMO.
As such, I expect a good deal for OM + IBD should be worth significantly more than $.50/share.
I do agree, though, that the probable deal date has most likely been moved back but I wouldn't put anything past Leo as to slipping in a deal soon when many are not expecting it.
At the current time we are all guessing. I do agree that those with dry powder now are sitting on a very attractive investment in IPIX at the current pricing.
The recent gastric test showed very positive results for the successful formulation of such a pill - again IMO.
As such, I expect a good deal for OM + IBD should be worth significantly more than $.50/share.
I do agree, though, that the probable deal date has most likely been moved back but I wouldn't put anything past Leo as to slipping in a deal soon when many are not expecting it.
At the current time we are all guessing. I do agree that those with dry powder now are sitting on a very attractive investment in IPIX at the current pricing.
(2)
(0)
